Bioanalytical CROs at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

30 bioanalytical CROs are at EBF 2026 — 40 presentations on the program. Most represented: Charles River Laboratories (5 on the program), BioAgilytix (4 on the program), ICON (4 on the program). 27 of them have their own page in this guide. As of Oct 13, 2026.

All 63 organizations at EBF 2026 →

Showing 1–13 of 30 organizations

Organization	EBF 2026 Attendance
Charles River Laboratories Wilmington, Massachusetts	◇Sponsor
criver.com Bioanalytical CROsSponsor Contract research organization providing discovery, safety assessment and bioanalysis services for drug developers.	Talk Tue Nov 17 12:10–12:30pm Part of Session 3: Vaccines Harmonizing Validation of Vaccine Immunogenicity Assays: A Fit-for-Purpose Framework for Quantitative and Semi-Quantitative Methods Vaccines · Immunogenicity Talk Tue Nov 17 2:20–2:40pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows Transition from Duplicate to Singlicate ADA Testing: A Retrospective Evaluation of Clinical Immunogenicity Data Immunogenicity · Sampling Talk Tue Nov 17 5–5:20pm Part of Session 8: Pharma CRO Analytical Challenges of Gas Shuttling Nanomedicine: A case study of Inter-CRO Transfer of a Bioanalytical Method for Complex Modalities New modalities Talk Wed Nov 18 12–12:20pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 Rethinking In-Study Cut Point Application for siRNA Immunogenicity Assessment When False Positive Rates Fall Outside the Conventional Range Immunogenicity · New modalities Talk Thu Nov 19 12:10–12:30pm Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions Decoding ADC Complexity: Bioanalytical LC-MS Approaches and application to preclinical and clinical studies New modalities · LC–MS
BioAgilytix Durham, North Carolina	◇Sponsor
bioagilytix.com Bioanalytical CROsSponsor Bioanalytical CRO specialising in large-molecule PK, immunogenicity, biomarker and cell-based assays, with labs in the US and Europe.	Talk Tue Nov 17 11:50am–12:10pm Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Fit-for-Purpose Implementation of a Generic Preclinical PK Assay: Lessons from Platform Transfer and Troubleshooting Ligand binding Talk Tue Nov 17 5:40–6pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR Considering DNA & RNA Extraction for PCR-Based Assay Validations PCR Talk Wed Nov 18 12:20–12:40pm Part of Session 13: BioA Clinic Cross-Platform Evaluation of Total Antibody and Total ADC PK: LBA versus LC-MS New modalities · LC–MS Talk Thu Nov 19 11:10–11:30am Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Responding to Evolving Clinical Needs: A Collaborative Journey to an Ultra-Sensitive PK Assay Ligand binding
ICON Dublin, Ireland	◇Sponsor
iconplc.com Bioanalytical CROsSponsor Global clinical research organization whose laboratories run central lab and regulated bioanalysis services.	Talk Tue Nov 17 4:20–4:40pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR How to validate qPCR assays in rare matrix such as ocular epithelial cells PCR Talk Thu Nov 19 9:20–9:40am Part of Session 15: Flow Implementation and validation of a 25-color immunophenotyping backbone with modular expansion toward 40-color spectral flow cytometry Cell-based Talk Thu Nov 19 9:40–10am Part of Session 16: Protein MS tech 1 The use of multiple signature peptides for quantitative protein bioanalysis by digestion and LC-MS/MS LC–MS Talk Thu Nov 19 2:40–3pm Part of Session 21: Protein MS Tech 2 Analytical aspects of LC-MS/MS-based neutralizing antibody testing LC–MS · Immunogenicity
Nuvisan Neu-Ulm, Germany	◇Sponsor
nuvisan.com Bioanalytical CROsSponsor CRO offering drug discovery, bioanalysis, clinical pharmacology and CMC services.	Talk Tue Nov 17 4:20–4:40pm Part of Session 7: BM CoU in practice Target Engagement Biomarkers: Context-of-Use Driven Assay Selection Biomarkers Talk Thu Nov 19 10–10:20am Part of Session 16: Protein MS tech 1 Overcoming High Soluble Target Interference in Drug Quantification: A Hybrid Immunocapture LC-MS/MS Approach for Clinical Bioanalysis LC–MS Talk Thu Nov 19 12:10–12:30pm Part of Session 18: Connecting Metabolism, Exposure and Multi-Omics Challenges and prospects of targeted metabolomics kits validation LC–MS · Biomarkers
QPS Newark, Delaware	◇Sponsor
qps.com Bioanalytical CROsSponsor CRO specialising in regulated bioanalysis, DMPK, toxicology and clinical research.	Talk Tue Nov 17 2:20–2:40pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics M10 Compliant Quan–Qual Analysis of Parent Oligonucleotides and Metabolites Using a Next-Generation QTOF Platform New modalities · LC–MS Talk Tue Nov 17 5–5:20pm Part of Session 7: BM CoU in practice Best Practices of Performing Parallelism in Biomarker Assays: A CRO Perspective Biomarkers Talk Wed Nov 18 9:40–10am Part of Session 12: Assay life cycle Challenges during implementation of new reagent lots Ligand binding
Resolian Malvern, Pennsylvania	◇Sponsor
resolian.com Bioanalytical CROsSponsor Bioanalytical and CMC analytical CRO formed from LGC's drug development business and Alliance Pharma, with labs in the US, UK, China and Australia.	Talk Tue Nov 17 2:40–3pm Part of Session 6: Biosimilars Demonstrating Antigenic Equivalence Across Biosimilars and Reference Products: ADA and NAb Assay Validation Strategies Through Real-World Case Studies Immunogenicity Talk Wed Nov 18 9:20–9:40am Part of Session 10: Bioanalysis Beyond Conventional Matrices Bioanalytical Challenges of PK Assessment in Nasal Mucosal Lining Fluid for a Novel Antiviral Therapeutic Sampling Talk Thu Nov 19 9–9:20am Part of Session 16: Protein MS tech 1 Extending the Sensitivity of a Hybrid LC-MS/MS Assay for PAD2 and PAD4 Through Microflow Chromatography LC–MS
Ardena Ghent, Belgium	◇Sponsor
ardena.com Bioanalytical CROsSponsor Drug development CDMO and CRO offering formulation, manufacturing and regulated bioanalysis services.	Talk Tue Nov 17 11:50am–12:10pm Part of Session 3: Vaccines Vaccine Ligand-Binding Assays for Clinical Sample Analysis: Qualification vs. Validation - A Fit-for-Purpose Approach to Dilution Series and Cut-Point Selection Vaccines · Ligand binding Talk Wed Nov 18 12–12:20pm Part of Session 13: BioA Clinic Analytical Challenges in Sphingolipid Quantification: Enabling Biomarker Discovery in Lysosomal and Neurodegenerative Disorders Biomarkers · LC–MS
Celerion Lincoln, Nebraska	◇Sponsor
celerion.com Bioanalytical CROsSponsor Clinical research organization running early-phase clinical pharmacology studies and regulated bioanalysis.	Talk Wed Nov 18 10–10:20am Part of Session 12: Assay life cycle Beyond Reagent Continuity: A Strategic Approach to Assay Life Cycle Management and Method Evolution Regulation Talk Wed Nov 18 12:40–1pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 PABAD in Action: Advancing Drug-Tolerant NAb Testing Immunogenicity
Intertek London, UK	◇Sponsor
intertek.com Bioanalytical CROsSponsor Testing and assurance group whose pharmaceutical services labs provide regulated bioanalysis and CMC testing.	Talk Wed Nov 18 11:20–11:40am Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 Did we get the context? Immunogenicity Talk Wed Nov 18 4:40–5pm Part of Workshop 10: ADA - Adaptive Tier Adaptive ADA Tiered approach: A Better Fit for Therapeutics with Pre-Existing Antibodies Immunogenicity
Labcorp Burlington, North Carolina	◇Sponsor
labcorp.com Bioanalytical CROsSponsor Laboratory services company whose drug development unit runs central lab, bioanalysis and early development services.	Talk Tue Nov 17 2:40–3pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows From Collection to Analysis: Evaluating Patient-Centric Dried Blood Microsampling Technologies for Regulated Bioanalysis Sampling Talk Tue Nov 17 5:20–5:40pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR Measuring Biological Response Using RT-qPCR: A Bioanalytical Perspective on Relative Gene Expression PCR · Biomarkers
Aliri Colorado Springs, Colorado	◇Sponsor
aliribio.com Bioanalytical CROsSponsor Bioanalytical CRO formed from Pyxant Labs and ImaBiotech, offering regulated LC–MS and ligand-binding bioanalysis and spatial bioanalysis, with labs in the US and France.	Talk Tue Nov 17 4:40–5pm Part of Session 7: BM CoU in practice When “How Much?” Is Not Enough: Adding the “Where” to Bioanalysis Biomarkers
Evotec Hamburg, Germany	◇Sponsor
evotec.com Bioanalytical CROsSponsor Drug discovery and development partner offering research, preclinical, bioanalysis and manufacturing services, including at its Aptuit site in Verona.	Talk Thu Nov 19 12:10–12:30pm Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Next-Generation Ultrasensitive Protein Detection in Huntington's Disease: from SMC™ to NULISA™ Technology Biomarkers
Institute Krems Bioanalytics Krems, Austria	◇Sponsor
krems-bioanalytics.com Bioanalytical CROsSponsor Contract research institute of IMC Krems University of Applied Sciences running GxP immunogenicity, PK and cell-based assays for large molecules and vaccines.	Talk Thu Nov 19 10–10:20am Part of Session 15: Flow Towards Harmonization of In Vitro T-Cell Assays: Lessons from the Development of a Naïve CD4+ T-Cell Proliferation Assay Cell-based